AU2017374458B2 - Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder - Google Patents

Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder Download PDF

Info

Publication number
AU2017374458B2
AU2017374458B2 AU2017374458A AU2017374458A AU2017374458B2 AU 2017374458 B2 AU2017374458 B2 AU 2017374458B2 AU 2017374458 A AU2017374458 A AU 2017374458A AU 2017374458 A AU2017374458 A AU 2017374458A AU 2017374458 B2 AU2017374458 B2 AU 2017374458B2
Authority
AU
Australia
Prior art keywords
bipolar disorder
formula
mania
group
bipolar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017374458A
Other languages
English (en)
Other versions
AU2017374458A1 (en
Inventor
Sei Myoung Han
Yu Jin Shin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of AU2017374458A1 publication Critical patent/AU2017374458A1/en
Application granted granted Critical
Publication of AU2017374458B2 publication Critical patent/AU2017374458B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017374458A 2016-12-14 2017-12-14 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder Active AU2017374458B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14
KR10-2016-0170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (2)

Publication Number Publication Date
AU2017374458A1 AU2017374458A1 (en) 2019-07-04
AU2017374458B2 true AU2017374458B2 (en) 2023-03-02

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017374458A Active AU2017374458B2 (en) 2016-12-14 2017-12-14 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Country Status (14)

Country Link
US (1) US11571410B2 (enExample)
EP (1) EP3556366B1 (enExample)
JP (1) JP7208139B2 (enExample)
KR (1) KR102635938B1 (enExample)
CN (1) CN110290788A (enExample)
AU (1) AU2017374458B2 (enExample)
BR (1) BR112019011930A2 (enExample)
CL (1) CL2019001618A1 (enExample)
ES (1) ES3054693T3 (enExample)
IL (1) IL267195B2 (enExample)
MX (1) MX2019006940A (enExample)
MY (1) MY199104A (enExample)
WO (1) WO2018111008A1 (enExample)
ZA (1) ZA201903747B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021003203A (es) * 2018-09-21 2021-05-27 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulacion que comprende el mismo en prevenir, aliviar, o tratar trastorno de estres agudo o trastorno de estres post-traumatico.
EP3854392A4 (en) * 2018-09-21 2022-08-17 SK Biopharmaceuticals Co., Ltd. USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES
KR20220104746A (ko) * 2019-11-22 2022-07-26 에스케이바이오팜 주식회사 카바메이트 화합물을 포함하는 경구용 약제학적 조성물 및 그 제조방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080005437A (ko) * 2005-04-22 2008-01-11 에스케이 주식회사 신경치료용 아졸 화합물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297732C (en) * 1997-08-14 2008-04-29 F. Hoffmann-La Roche Ag Heterocyclic vinylethers against neurological disorders
KR100843703B1 (ko) 2000-07-21 2008-07-04 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도
CZ20032300A3 (cs) * 2001-02-27 2005-01-12 Ortho-Mcneil Pharmaceutical, Inc. Léčivo pro prevenci nebo léčbu bipolárních chorob
HUP0303261A3 (en) * 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating bipolar disorder
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
CA2667909A1 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Treatment of pervasive developmental disorders
BRPI0924997B1 (pt) 2009-06-22 2024-01-16 Sk Biopharmaceuticals Co., Ltd Método para preparar um composto de éster do ácido 1-aril-2- tetrazoil etil carbâmico
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9981950B2 (en) * 2014-08-15 2018-05-29 Janssen Pharmaceuticals, Inc. Triazoles as NR2B receptor inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080005437A (ko) * 2005-04-22 2008-01-11 에스케이 주식회사 신경치료용 아졸 화합물

Also Published As

Publication number Publication date
EP3556366A1 (en) 2019-10-23
RU2019121913A (ru) 2021-01-15
JP2020502106A (ja) 2020-01-23
ZA201903747B (en) 2021-01-27
WO2018111008A1 (ko) 2018-06-21
KR102635938B1 (ko) 2024-02-13
CL2019001618A1 (es) 2019-08-23
US11571410B2 (en) 2023-02-07
RU2019121913A3 (enExample) 2021-04-21
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
IL267195A (enExample) 2019-07-31
KR20190087572A (ko) 2019-07-24
CA3046297A1 (en) 2018-06-21
BR112019011930A2 (pt) 2019-10-29
EP3556366B1 (en) 2025-10-22
CN110290788A (zh) 2019-09-27
US20190314337A1 (en) 2019-10-17
ES3054693T3 (en) 2026-02-05
IL267195B1 (en) 2024-01-01
MY199104A (en) 2023-10-13
MX2019006940A (es) 2019-09-06
AU2017374458A1 (en) 2019-07-04
JP7208139B2 (ja) 2023-01-18

Similar Documents

Publication Publication Date Title
JP7071287B2 (ja) 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用
EP3556366B1 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
AU2018370164B2 (en) Use of carbamate compound for reducing or treating developmental disorders including fragile X syndrome, Angelman syndrome or Rett syndrome
US20200223838A1 (en) Methods of use of phenoxypropylamine compounds to treat depression
AU2017267160B2 (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
AU2018367729B2 (en) Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure
AU2019344261B2 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
JP2022503784A (ja) てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
EP3556363B1 (en) Use of carbamate compound for prevention, alleviation or treatment of pruritus
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
RU2796295C2 (ru) Карбаматное соединение и применение включающей его композиции для профилактики, облегчения или лечения острого стрессового расстройства или посттравматического стрессового расстройства
CA3081223C (en) Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure
HK40005640A (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)